Table 1 Demographic data of study patients
Total | 1 × 3,000 IU/d | 2 × 3,000 IU/d | P-value | |
|---|---|---|---|---|
n | 62 | 32 | 30 | |
Sex (male) | 45/62 (72.6%) | 20/32 (62.5%) | 25/30 (83.3%) | 0.09 |
Age (years) | 63 ± 12 | 60 ± 14 | 66 ± 10 | 0.038a |
BMI | 25 ± 4.2 | 25 ± 5 | 25 ± 3.3 | 0.924 |
Admission diagnoses (n/%) | 0.17 | |||
Multiple trauma | 10/62 (16.1) | 5/32 (15.5) | 5/30 (16.6) | |
Pulmonary disease | 4/62 (6.4) | 1/32 (3.1) | 3/30 (10) | |
Cardiac disease | 22/62 (35.5) | 9/32 (39.1) | 13/30 (43.3) | |
Infectious disease | 5/62 (8.1) | 3/32 (9.4) | 2/30 (6.6) | |
Neoplasm | 12/62 (19.4) | 9/32 (39.1) | 3/30 (10) | |
Orthopedic disease | 3/62 (4.8) | 2/32 (6.3) | 1/30 (3.3) | |
Other | 6/62 (9.7) | 3/32 (9.4) | 3/30 (10) | |
CV drug requirement (n/%) | 25/62 (40.3) | 13/32 (40.6) | 12/30 (40) | 1 |
Dopamine | 6/62 (9.7) | 5/32 (15.5) | 1/30 (3.3) | |
Phenylephrine | 16/62 (25.8) | 10/32 (31.2) | 6/30 (20) | |
Norepinephrine | 7/62 (11.3) | 2/32 (6.25) | 5/30 (16.6) | |
Adrenaline | 3/62 (4.8) | 1/32 (3.1) | 2/30 (6.6) | |
Vasopressin | 2/62 (3.2) | 1/32 (3.1) | 1/30 (3.3) | |
Milrinone | 13/62 (21) | 5/32 (15.5) | 8/30 (26.6) | |
MODS (pts) | 4.1 ± 2.1 | 4.1 ± 2.4 | 4.2 ± 1.8 | 0.801 |
Length of ICU stay (days) | 12 ± 11 | 10 ± 12 | 13 ± 11 | 0.301 |
ICU mortality | 2/62 (3.2%) | 1/32 (3.1%) | 1/30 (3.3%) | 1 |